<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03187509</url>
  </required_header>
  <id_info>
    <org_study_id>2017-7615</org_study_id>
    <nct_id>NCT03187509</nct_id>
  </id_info>
  <brief_title>Weight-Based Torsemide Dosing in Subjects With Heart Failure</brief_title>
  <official_title>Weight-Based Torsemide Dosing vs. Standard Outpatient Management in Subjects With Heart Failure: A Randomized Open-Label Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York City Health and Hospitals Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York City Health and Hospitals Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a randomized open-label pilot study. The purpose of the study is to
      compare standard of care outpatient heart failure management versus a weight based torsemide
      regimen. Subjects admitted to the hospital for heart failure exacerbation will be randomized
      upon discharge to either standard of care outpatient heart failure management or a weight
      based torsemide regimen. Those subjects randomized to standard of care therapy will be
      prescribed a daily fixed dose of a loop diuretic at hospital discharge and have a follow-up
      appointment within one week of discharge. All management decisions including loop diuretic
      type, dose and frequency will be made at the discretion of the subject's personal physician.
      Those randomized to an individualized weight based torsemide regimen will be prescribed a
      dose of torsemide upon hospital discharge based on a prespecified algorithm. These subjects
      will then undergo physician-subject phone encounters three times a week where the subject's
      torsemide dose will be modified based on the prespecified algorithm which incorporates
      current symptoms and weight. Primary end-point will be an unbiased estimate of 30-day all
      cause readmission rates. Secondary end-points include incidence of acute kidney injury,
      changes in brain natriuretic peptide levels from baseline and a preliminary estimate of the
      effect size and feasibility of a weight-based torsemide regimen intervention in order to plan
      a future larger study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be an open-label parallel randomized pilot study comparing an individualized
      weight-based torsemide dosing regimen vs. standard outpatient management in patients with a
      diagnosis of heart failure.The study will include consenting subjects who are admitted to
      Jacobi Medical Center with heart failure and were treated with loop diuretic therapy during
      hospitalization. Prior to discharge, these subjects will be randomized to one of two groups,
      either an individualized weight-based torsemide regimen group vs. a standard heart failure
      management group.

      After randomization, all subjects will undergo an initial assessment prior to discharge. All
      subjects will be examined, weighed and assigned a composite congestion score (CCS). CCS is a
      measurement of current fluid status that has been shown to correlate with clinical outcomes
      in heart failure patients (19). It assesses a patient's signs and symptoms of congestion,
      including dyspnea, orthopnea, fatigue, jugular venous distention, rales and peripheral edema.
      Each category is given a score from 0-3, 0=none, 1=mild,2=moderate and 3=severe. Each subject
      is given a final composite score for their current volume status.

      After discharge, those randomized to standard care will receive standard heart failure care
      as currently provided in our institution. This routinely includes, but is not limited to, an
      appointment with their primary care physician within one week of discharge, nutrition
      consultation, and social work evaluation with support services provided as determined by the
      social worker. At discharge, all heart failure medication changes including diuretic type,
      dose and frequency, as well as further management decisions, will be left to the discretion
      of the subject and the subject's doctors. Those who will be randomized to the individualized
      weight-based torsemide regimen will be given a standup home scale and torsemide 20mg tabs in
      a bottle with 100 tablets.

      An initial torsemide dose will be assigned based on the patient's GFR and CCS at discharge.
      These subjects will then have a phone encounter with a physician three times a week where
      subjects will be instructed to modify the torsemide dose based on their current weight.
      Patients will be instructed to weigh themselves at the same time of the day, postvoid, prior
      to eating, prior to the medication dose, and while wearing the same clothing for consistency.
      The scales should stand on a flat, solid surface rather than carpets unless specifically
      designed for use in that setting. All phone call encounters and loop diuretic changes will be
      based on the pre-specified algorithm. These subjects will also receive all the same care and
      support as a standard subject, including the primary care appointment in one week and other
      support services, except with instructions to the subject and provider to follow the loop
      diuretic recommendations from this protocol. Subjects who have been instructed to take more
      than 80 torsemide 20mg tablets will receive a delivery of 100 additional torsemide 20mg
      tablets.

      All subjects in the study will have follow up visit at week 5 from discharge date. Total
      diuretic use during the study period will be assessed and current symptoms/quality of life
      will be evaluated using the Kansas City Cardiomyopathy Questionnaire. The patient will
      receive a physical examination including a final weight and calculation of composite
      congestion score. Serum B-type natriuretic peptide (BNP) will be obtained as well as a basic
      metabolic panel and serum magnesium level to assess for electrolyte disturbances and changes
      in kidney function. Intervention group subjects will have a count of the remaining number of
      torsemide tablets in the bottle of torsemide given to them at discharge. Compliance with the
      algorithm will be assessed by comparing the number of remaining tablets with the number of
      tablets prescribed during the study. Subjects whose follow-up visit occurs over 45 days after
      the date of hospital discharge for the enrollment hospitalization shall be deemed to be late
      for follow-up. Acute kidney injury (AKI) will be defined as an increase in serum creatinine
      concentration of 0.3 at the five-week follow-up visit compared to the final serum creatinine
      level measured during hospitalization. Adherence will be measured by comparing the number of
      tablets in the subject's torsemide supply to the number of expected tablets in the torsemide
      supply. Adherence will be defined as a tablet count consistent with the subject having taken
      88% or more of the expected torsemide tablets
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2018</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>30-day all-cause readmission rate</measure>
    <time_frame>30 days from enrollment</time_frame>
    <description>To gain an unbiased estimate of 30-day all-cause hospital readmission rate with an individualized weight-based torsemide dosing regimen and with standard therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect size of weight based torsemide regimen compared to standard therapy</measure>
    <time_frame>30 days from enrollment</time_frame>
    <description>To obtain a preliminary estimate of the effect size of an individualized weight-based torsemide regimen intervention using contemporaneous controls of standard care for planning a potential, larger future study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of a weight based torsemide regimen</measure>
    <time_frame>30 days from enrollment</time_frame>
    <description>To assess the feasibility of subjects to follow an individualized weight-based torsemide regimen as assessed by compliance with study medications, adhering to thrice weekly phone encounters and following medication dose modifications based on the study algorithm. Compliance with the study medication and algorithm will be assessed at the final study appointment by comparing the number of remaining torsemide tablets in the subject's pill box which was provided at the beginning of the study with the number of tablets prescribed during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute kidney injury (AKI)</measure>
    <time_frame>30 days from enrollment</time_frame>
    <description>To gain an unbiased estimate of AKI incidence, as defined by an increase serum creatinine by â‰¥0.3 mg/dL from baseline, with an individualized weight-based torsemide dosing regimen and with standard therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of baseline changes of brain natriuretic peptide (BNP) levels</measure>
    <time_frame>30 days from enrollment</time_frame>
    <description>To compare changes in BNP(pg/mL) levels from baseline in subjects randomized to a weight-based torsemide regimen and those randomized to standard therapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Weight-Based Torsemide Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to complete a weight-based torsemide dosing regimen for their outpatient heart failure management. These subjects will prescribed a specified dose of torsemide on discharge from the hospital and subsequently have a phone encounter with a physician three times a week where their dose of torsemide will be titrated based on an algorithm which factors in current symptoms and weight. Study subjects will have a final follow-up appointment at the completion of the study to evaluate current symptoms, weight and perform blood work to assess kidney function, electrolytes and brain natriuretic peptide levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Outpatient Management Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be randomized to standard outpatient heart failure management where they will be prescribed a fixed daily dose of a loop diuretic upon discharge from the hospital and have a follow-up appointment within one week of discharge. All medications including loop diuretic type, dose and frequency will be managed at the discretion of the patient's primary care physician or cardiologist. Study subjects will have a final follow-up appointment at the completion of the study to evaluate current symptoms, weight and perform blood work to assess kidney function, electrolytes and brain natriuretic peptide levels.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Torsemide</intervention_name>
    <description>These subjects who are randomized to a weight-based torsemide regimen will be instructed via phone encounters three times per week to take an individualized dose of torsemide based on their current weight and symptoms. These subjects will have a follow-up study appointment at week 5 for a final weight and blood work to assess kidney function, electrolytes and brain-natriuretic peptide levels.</description>
    <arm_group_label>Weight-Based Torsemide Group</arm_group_label>
    <other_name>Demadex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Outpatient Heart Failure Management</intervention_name>
    <description>Those subjects randomized to standard outpatient management group will be prescribed a daily fixed dose of a loop diuretic upon discharge from the hospital. These subjects will have a follow-up appointment within one week of discharge where all medications including loop diuretic type, dose and frequency will be managed at the discretion of the subject's physician. These subjects will also have a follow-up study appointment at week 5 for a final weight and blood work to assess kidney function, electrolytes and brain-natriuretic peptide levels.</description>
    <arm_group_label>Standard Outpatient Management Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All subjects with admission diagnosis of heart failure, including heart failure with
             reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF) treated with
             loop diuretics during hospitalization

          2. Must be at least 18 years old at time of enrollment

          3. Must have reliable access to a telephone, and be able to speak and understand English
             or Spanish over a telephone connection

        Exclusion Criteria:

          1. Any subject who is currently pregnant

          2. Any subject with end-stage renal disease requiring hemodialysis

          3. Any subject with serum potassium concentration &lt; 3.5 mEq/L at discharge

          4. Any subject with serum magnesium concentration &lt; 1.4 mg/dL at discharge

          5. Any subject with a known history of allergic reaction to loop diuretics

          6. Any subject with known severe stenotic valvular heart disease

          7. Any subject who requires chronic inotropic pharmacotherapy

          8. Any subject undergoing evaluation for cardiac transplantation or left-ventricular
             assist device

          9. Any subject who is not able to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Siegel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jacobi Medical Center, Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Siegel, MD</last_name>
    <phone>718-918-5900</phone>
    <email>robert.siegel@nychhc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeremy Miles, MD</last_name>
    <email>milesj@nychhc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jacobi Medical Cent</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert M Seigel, MD</last_name>
      <phone>718-918-5900</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 9, 2017</study_first_submitted>
  <study_first_submitted_qc>June 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2017</study_first_posted>
  <last_update_submitted>July 24, 2019</last_update_submitted>
  <last_update_submitted_qc>July 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York City Health and Hospitals Corporation</investigator_affiliation>
    <investigator_full_name>Robert Siegel</investigator_full_name>
    <investigator_title>Director of CCU, Jacobi Medical Center, Assistant Professor of Medicine, Albert Einstein College of Medicine</investigator_title>
  </responsible_party>
  <keyword>Torsemide, loop diuretics, weight-based</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Torsemide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

